High throughput screening aids clinical decision‐making in refractory acute myeloid leukaemia

Despite advances in therapeutics for adverse‐risk acute myeloid leukaemia (AML), overall survival remains poor, especially in refractory disease. Comprehensive tumour profiling and pre‐clinical drug testing can identify effective personalised therapies.

• Publication year

  2024

• Venue

  Cancer Reports

• Publication date

  2024-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cnr2.2061PMID 38662349PMCID 11044912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High throughput screening aids clinical decision‐making in refractory acute myeloid leukaemia

  2024cited by this paper
• High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

  2023cited by this paper
• A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

  2022cited by this paper
• Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies

  2022cited by this paper
• Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials

  2022cited by this paper
• Venetoclax resistance: mechanistic insights and future strategies

  2022cited by this paper
• Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

  2021cited by this paper
• In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer

  2021cited by this paper
• Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities

  2020cited by this paper
• Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study.

  2020cited by this paper
• Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

  2020cited by this paper
• Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

  2020cited by this paper
• Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.

  2020cited by this paper
• Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

  2019cited by this paper
• Efficacy and Feasibility of Allogeneic Hematopoietic Stem‐Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia

  2019cited by this paper
• JAK2-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases

  2019cited by this paper
• A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

  2019cited by this paper
• Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

  2019cited by this paper
• Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

  2019cited by this paper
• Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

  2018cited by this paper
• Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

  2017cited by this paper
• Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies

  2017cited by this paper
• A Rare Case of ETV6/MECOM Rearrangement in Therapy-Related Acute Myeloid Leukemia with t(3;12) and Monosomy 7.

  2017cited by this paper
• Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

  2017cited by this paper
• Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

  2016cited by this paper
• A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

  2015cited by this paper
• t(3;12)(q26;p13) ETV6/MECOM - t(3;12)(q26;p13) ETV6/EVI1

  2014cited by this paper
• Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

  2013cited by this paper
• Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.

  2012cited by this paper
• Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

  2012cited by this paper
• Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

  2010cited by this paper
• Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

  2010cited by this paper
• The JAK2 V617F mutation in de novo acute myelogenous leukemias

  2006cited by this paper

• High throughput screening aids clinical decision‐making in refractory acute myeloid leukaemia

  2024cites this paper